These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Preferential reduction of nm23-H1 gene product in metastatic tissues from papillary and follicular carcinomas of the thyroid.
    Author: Arai T, Yamashita T, Urano T, Masunaga A, Itoyama S, Itoh K, Shiku H, Sugawara I.
    Journal: Mod Pathol; 1995 Apr; 8(3):252-6. PubMed ID: 7617649.
    Abstract:
    The nm23 gene product is a possible mediator of cancer invasion and metastasis, and has been divided into two distinct gene products, NM23-H1 and NM23-H2. It has been shown previously that expression of nm23-H1 messenger RNA is reduced in metastatic lymph nodes from patients with papillary carcinoma of the thyroid (Am J Pathol 142:1938-1944, 1993). Since mAb H1-229 specific for NM23-H1 is now available, we further extended our study to examine the expression of nm23-H1 gene product in various types of thyroid cancer (37 cases of papillary carcinoma, 42 cases of follicular carcinoma, 17 cases of anaplastic carcinoma, and 3 cases of medullary carcinoma). NM23-H1 was expressed in primary papillary and follicular carcinomas (14/15 and 21/22), but weakly or hardly expressed in metastatic lymph nodes and metastatic bone marrow (6/23 and 1/4) (P < 0.01). Expression of NM23-H1 was low or absent in anaplastic and medullary carcinoma (3/17 and 0/3) (P < 0.01).
    [Abstract] [Full Text] [Related] [New Search]